NCT03265080View on ClinicalTrials.gov

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

October 24, 2019

Study Completion Date

November 12, 2020

Conditions
Colon Cancer MetastaticHead and Neck Cancer MetastaticMetastatic Non-Small Cell Lung CancerUrothelial CarcinomaMetastatic Melanoma
Interventions
BIOLOGICAL

ADXS-NEO

Intravenous infusion

BIOLOGICAL

Pembrolizumab

Intravenous infusion

Trial Locations (5)

70121

Ochsner Clinic Foundation - Ochsner Cancer Institute, New Orleans

85258

Honor Health, Scottsdale

90404

UCLA, Los Angeles

07960

Atlantic Health System, Morristown

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

Advaxis, Inc.
All Listed Sponsors
lead

Advaxis, Inc.

INDUSTRY

NCT03265080 - A Study of ADXS-NEO Expressing Personalized Tumor Antigens | Biotech Hunter | Biotech Hunter